UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone

Experimental and Molecular Medicine, 2023, 55(0), , pp.470-484

2023

Volltextzugriff (PDF)

Prx1 suppresses radiation-induced c-jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase pi/c-jun NH2-terminal kinase complex

Cancer research (Chicago, Ill.), 2006-07, Vol.66 (14), p.7136-7142

2006

Volltextzugriff (PDF)

Hetero- and Autoprocessing of the Extracellular Metalloprotease (Mpr) in Bacillus subtilis

Journal of Bacteriology, 2004-10, Vol.186 (19), p.6457-6464

2004

Volltextzugriff (PDF)

Abstract PS10-18: Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS10-18-PS10-18

2021

Volltextzugriff (PDF)

Abstract 1483: A novel anti-Tie2 antibody stabilizes vessel and increases tumor infiltrated lymphocytes

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1483-1483

2020

Volltextzugriff (PDF)

Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14545-e14545

2020

Volltextzugriff (PDF)

Effect of molecular imaging on validation of developed anti-hVEGFR2 therapeutic antibody

Cancer biotherapy & radiopharmaceuticals, 2011-12, Vol.26 (6), p.745-751

2011

Volltextzugriff (PDF)

PP069 PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME

ESMO open, 2023-12, Vol.8 (1), p.102149, Article 102149

2023

Volltextzugriff (PDF)

Abstract 1626: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1626-1626

2021

Volltextzugriff (PDF)

CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & EFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS: FINAL REPORT

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii44-ii45

2020

Volltextzugriff (PDF)

Abstract 5970: Tumor vessel normalization by a novel anti-TIE2 antibody PMC-403 enhances the effectiveness of radiation therapy on cancer therapy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5970-5970

2022

Volltextzugriff (PDF)

A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e13522-e13522

2017

Volltextzugriff (PDF)

Abstract 5557: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5557-5557

2022

Volltextzugriff (PDF)

Enhanced protease cleavage efficiency on the glucagon-fused interleukin-2 by the addition of synthetic oligopeptides

Protein expression and purification, 2007-09, Vol.55 (1), p.159-165

2007

Volltextzugriff (PDF)

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Investigational new drugs, 2017-12, Vol.35 (6), p.782-790

2017

Volltextzugriff (PDF)

ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi17-vi17

2017

Volltextzugriff (PDF)

NMR mapping of the highly flexible regions of 13C/15N-labeled antibody TTAC-0001-Fab

Journal of biomolecular NMR, 2020-07, Vol.74 (6-7), p.311-319

2020

Volltextzugriff (PDF)

A ligand-independent Tie2-activating antibody reduces vascular leakage in models of Clarkson disease

Science advances, 2023-11, Vol.9 (46), p.eadi1394-eadi1394

2023

Volltextzugriff (PDF)

TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

mAbs, 2015-09, Vol.7 (5), p.957-968

2015

Volltextzugriff (PDF)

NMR mapping of the highly flexible regions of 13 C/ 15 N-labeled antibody TTAC-0001-Fab

Journal of biomolecular NMR, 2020-07, Vol.74 (6-7), p.311

2020

Volltextzugriff (PDF)

Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2

Drug design, development and therapy, 2018, Vol.12, p.495-504

2018

Volltextzugriff (PDF)

Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2522-2522

2015

Volltextzugriff (PDF)

Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis

mAbs, 2015, Vol.7 (6), p.1195-1204

2015

Volltextzugriff (PDF)

Abstract 4244: TTAC-0001, fully human anti-VEGFR2/KDR neutralizing antibody blocks tumor angiogenesis and tumor growth

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4244-4244

2011

Volltextzugriff (PDF)

Abstract 647: TTAC-0001, anti-VEGFR2/KDR monoclonal antibody, inhibits VEGFR signaling and tumor growth in preclinical models

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.647-647

2011

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(34)
Humans
(26)
Biological And Medical Sciences
(13)
Female
(12)
Physical Sciences
(11)
Animals
(9)
Chemistry
(9)
Middle Aged
(9)
Oncology
(9)
Medical Sciences
(8)
Technology
(8)
Male
(7)
Adult
(6)
Aged
(6)
Chemistry, Multidisciplinary
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Materials Science
(6)
Mice
(6)
Treatment Outcome
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone

Prx1 suppresses radiation-induced c-jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase pi/c-jun NH2-terminal kinase complex

Hetero- and Autoprocessing of the Extracellular Metalloprotease (Mpr) in Bacillus subtilis

Abstract PS10-18: Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer

Abstract 1483: A novel anti-Tie2 antibody stabilizes vessel and increases tumor infiltrated lymphocytes

Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM)

Effect of molecular imaging on validation of developed anti-hVEGFR2 therapeutic antibody

PP069 PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME

Abstract 1626: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC)

CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & EFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS: FINAL REPORT

Abstract 5970: Tumor vessel normalization by a novel anti-TIE2 antibody PMC-403 enhances the effectiveness of radiation therapy on cancer therapy

A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM)

Abstract 5557: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME

Enhanced protease cleavage efficiency on the glucagon-fused interleukin-2 by the addition of synthetic oligopeptides

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)

NMR mapping of the highly flexible regions of 13C/15N-labeled antibody TTAC-0001-Fab

A ligand-independent Tie2-activating antibody reduces vascular leakage in models of Clarkson disease

TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

NMR mapping of the highly flexible regions of 13 C/ 15 N-labeled antibody TTAC-0001-Fab

Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2

Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors

Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis

Abstract 4244: TTAC-0001, fully human anti-VEGFR2/KDR neutralizing antibody blocks tumor angiogenesis and tumor growth

Abstract 647: TTAC-0001, anti-VEGFR2/KDR monoclonal antibody, inhibits VEGFR signaling and tumor growth in preclinical models

Suchergebnisse filtern